V1.6 Indication Expansion // Paired Myelofibrosis Flagships + 4 Comparative Cohorts + Live 7,000-Disease Edge MCP Engine
Four High-Tractability Hematology & Immunology Orphan Expansions Benchmarked Against Myelofibrosis
Benchmarked directly against our Paired Flagships—Clonal JAK2 V617F+ Primary Myelofibrosis (jak2-myelofibrosis) and Reversible Autoimmune Myelofibrosis (AIMF) + Dual Transfusional/Hepcidin Iron Overload (autoimmune-myelofibrosis)—v1.6 exposes eight zero-wet-lab-ready AI-bio, EHR diagnostic, and Rare Pediatric PRV startup blueprints across VEXAS Syndrome (UBA1), Idiopathic Multicentric Castleman Disease (iMCD), Systemic Mastocytosis (KIT D816V), and Telomere Biology Disorders (TERT/TERC/PAPD5), plus a live federated read-verb tool (search_any_orphan_indication; legacy alias analyze_any_orphan_indication supported) covering all 7,000+ orphan diseases on https://api.rare-disease-atlas.workers.dev/mcp.
1. Comparative Tractability & Commercial Matrix
| Indication (Slug & Orphanet) | Causal Mechanism & US Patient Scale | Standard-of-Care Failure Cliff | Key Open Datasets, Structures & Active Trials |
|---|---|---|---|
VEXAS Syndromevexas-syndrome · ORPHA:597743 |
Somatic X-linked UBA1 p.Met41 loss of UBA1b (~1 in 4,269 men >50; ~15,000+ US adults) |
Zero FDA-approved drugs; >80% undiagnosed for 4–7 yrs despite routine MCV >100 fL + high CRP; lethal chronic steroid toxicity |
GEO:GSE163683 (scRNA/CITE-seq), PDB:6DC6, PAXIS pacritinib (NCT06538181), NIH Allo-HSCT (NCT05027945) |
Castleman Disease (iMCD & TAFRO)castleman-disease · ORPHA:93685 |
IL-6 / VEGF / PI3K-mTOR / JAK-STAT cytokine storm (~1,500–2,000 US iMCD; TAFRO causes marrow reticulin fibrosis) | 60–66% fail sole approved anti-IL-6 mAb (siltuximab); ICU misdiagnosis of TAFRO vs SLE/AIMF or lymphoma | HuggingFace:everycure KG, Sirolimus Phase 2 (NCT03933904), CDCN ACCELERATE Biobank |
Systemic Mastocytosissystemic-mastocytosis · ORPHA:2467 |
Somatic KIT D816V activation-loop kinase (>90% of ~30,000+ US Indolent & Advanced SM patients) |
First-gen avapritinib crosses BBB (cognitive/CNS bleed liability); 6–8 yr diagnostic delay from low-VAF blood false negatives & TPSAB1 HaT confounding |
PDB:4U0I, PDB:1T46, SUMMIT bezuclastinib (NCT05186753), HARBOR elenestinib (NCT04910685), PIONEER (NCT03731260) |
Telomere Biology Disorders / DCtelomere-biology-disorders · ORPHA:1775 |
Germline TERT, TERC, DKC1, PARN, RTEL1 (<1st percentile telomeres; pediatric DC + ~15–20% of familial IPF) |
Zero targeted drugs (danazol causes hepatotoxicity/virilization); unrecognized adult cryptic TBD suffers >50% fatal standard BMT conditioning toxicity | PDB:7BG9 (Cryo-EM telomerase), NIH Danazol (NCT01441037), Alkylator-Free BMT (NCT01659606), $100M–$158M Rare Pediatric PRV eligible |
2. Eight Concrete Startup & Translational Blueprints
[AI-BIO-05]VEXAS UBA1c-to-UBA1b Rescue & Synthetic-Lethal UPR Screen: PairPDB:6DC6+ VEXAS marrow scRNA-seq (GSE163683) with outsourced isogenicUBA1-M41CRO panels ($110K–$300K validation).[PUBLIC-HEALTH-05]Automated EHR Macrocytic-Inflammation VEXAS Triage: Non-device CDS rule (MCV >100 fL+ CRP/ESR + refractory chondritis/Sweet syndrome/VTE in adults ≥50) triggering peripheralUBA1exon 3 reflex testing.[AI-BIO-06]Siltuximab-Refractory iMCD Proteomic Endotyping & 505(b)(2) JAK/mTOR Repurposing: Stratify the 66% anti-IL-6 non-responder cohort using serum proteomics + Every Cure's open graph toward oral mTOR/JAK salvage (NCT03933904).[PUBLIC-HEALTH-06]Foundation-Model iMCD-TAFRO Lymph-Node & Marrow Pathology Triage: Score CDCN's 5 consensus histopathological grades + TAFRO lab criteria in 24 hours to prevent fatal ICU misdiagnosis.[AI-BIO-07]CNS-Excluded (Kp,uu < 0.02) & WT-SparingKIT D816VDegraders: P-gp efflux-tuned heterobifunctional degraders eliminating mast-cell clone burden without avapritinib cognitive side effects.[PUBLIC-HEALTH-07]Peripheral 0.01%-VAFKIT D816VddPCR +TPSAB1Copy-Number Allergy/GI Funnel: REMA-score + tryptase-adjusted screening across anaphylaxis & refractory GI clinics.[AI-BIO-08]Oral Non-HormonalPAPD5 (TENT4B)Inhibitor Restoring EndogenousTERCRNA: Unlocks an FDA Rare Pediatric Disease Priority Review Voucher ($100M–$158M comps) in Dyskeratosis Congenita before expanding into adult telomere-driven pulmonary fibrosis.[PUBLIC-HEALTH-08]Pre-Transplant Cryptic TBD Genomic & Flow-FISH Safety Gate: Prevents fatal busulfan/alkylator conditioning toxicity by routing cryptic adult TBD patients to radiation/alkylator-free protocols (NCT01659606).
3. Query All 6 Deep-Dives + Any of 7,000+ Orphan Diseases Live via MCP (`v1.6.0`) or DuckDB
Connect zero-install Streamable HTTP MCP (2026-07-28 & 2025-11-25) at https://api.rare-disease-atlas.workers.dev/mcp and call our 6 canonical read-verb tools—search_founder_opportunities, get_disease_case_study, list_non_dilutive_grants, get_validation_communities, get_90_day_validation_plan, and search_any_orphan_indication (legacy aliases match_founder_opportunities, find_non_dilutive_grants, generate_90_day_validation_plan, and analyze_any_orphan_indication remain supported)—for live OpenTargets + ClinicalTrials.gov v2 + PubMed + FDA Orphan unit economics benchmarked against Clonal JAK2 V617F+ and Reversible Autoimmune Myelofibrosis:
claude mcp add --transport http orphan-disease-atlas https://api.rare-disease-atlas.workers.dev/mcp
Or query the Hugging Face Parquet dataset directly in 3 lines of DuckDB SQL:
INSTALL httpfs; LOAD httpfs;
SELECT id, disease_id, capital_tier, title
FROM 'https://huggingface.co/datasets/rare-disease-atlas/rare-disease-venture-atlas/resolve/refs%2Fconvert%2Fparquet/default/train/0000.parquet';